Calcineurin inhibition protects against dopamine toxicity and attenuates behavioral decline in a Parkinson's disease model.

ABSTRACT:

Background

Parkinson's disease (PD), a highly prevalent neuro-motor disorder is caused due to progressive loss of dopaminergic (DAergic) neurons at substantia nigra region of brain. This leads to depleted dopamine (DA) content at striatum, thus affecting the fine tuning of basal ganglia. In patients, this imbalance is manifested by akinesia, catalepsy and tremor. PD associated behavioral dysfunctions are frequently mitigated by l-DOPA (LD) therapy, a precursor for DA synthesis. Due to progressive neurodegeneration, LD eventually loses applicability in PD. Although DA is cytotoxic, it is unclear whether LD therapy can accelerate PD progression or not. LD itself does not lead to neurodegeneration in vivo, but previous reports demonstrate that LD treatment mediated excess DA can poten

SUBMITTER: Mondal R 

PROVIDER: S-EPMC10394860 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature